Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok4. fázis

Atomoxetine and Executive Function in PTSD

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
Charleston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
160 fő, tervezett
Kezdés
2026. ápr. 1.
Várható befejezés
2029. szept. 28.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Atomoxetine
  • Placebo
A regiszteradat frissítve
2026. július 7.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Veterans ages 18 to 75 with PTSD and AD (CAPS > 35 for age 18 to 64, CAPS > 25 for age 65 to 75; CAARS-S:S > 60); The cut-score of 25 used for participants age 65 to 75 because lower cut-score has been recommended for older Veterans (Yeager and Magruder, 2014); ADHD has been recognized as a neurobehavioral impairment in executive function (Brown, 2008); Veterans with PTSD at this age range are suited for this study because statistically they have fewer confounding variables for this clinical trial, including medical conditions such as hypertension or glaucoma and cognitive impairments such as dementia
  • Physical health good enough to be able to participate in the study
  • Competent to give informed consent

Ki nem vehet részt

  • Use of concomitant medication that could potentially interact with atomoxetine including monoamine oxidase inhibitors (MAOI), antihypertensive medication, or any concomitant medication that is a cytochrome 2D6 (CYP2D6) inhibitor, such as paroxetine, venlafaxine, fluoxetine, because atomoxetine's elimination involves the CYP2D6 system
  • Subjects who are currently taking psycho-stimulants, other NRIs such as duloxetine, and venlafaxine will be excluded; However, the investigators will allow subjects who stopped the psycho-stimulant or other NRI or other SSRIs 2 weeks prior to the start of the trial
  • Subjects receiving active ongoing therapy with good response at the point of recruitment; The project will allow approved standard therapies, including psycho- or/and pharmacotherapies be continued with the condition that the subjects continue to present with PTSD symptoms severe enough to meet the inclusion criteria
  • Females who are pregnant or desired to become pregnant during the clinical trial period; Urine pregnancy tests will be performed at each of the visits, including prior to, during, and after the clinical trial
  • Presence of disorders that could conceivably be exacerbated by atomoxetine; specifically, narrow angle closure glaucoma, urinary outflow obstruction, hypertension, and neurological disorders, particularly tics and Tourette's syndrome, or a history of epilepsy or seizures
  • An active or lifetime major mental health diagnosis as determined by DSM-5 major psychiatric disorders, including:; schizophrenia; schizoaffective disorder; psychotic disorder not otherwise specified; bipolar I disorder, bipolar II disorder; bipolar disorder not otherwise specified; The project will allow the presence of depressive disorders if the depressive episodes are secondary to PTSD
  • Current substance use disorders:; DSM-5 alcohol; marijuana; and/or other drug use disorders in the last 3 months; Mild alcohol and marijuana use which does not meet the criteria for mild use disorder, such as occasional or recreational use will be permitted on a case by case basis
  • Age younger than 18 or greater than 75; Age becomes the main risk factor for major neurocognitive disorder, especially after 75 (Sousa et al, 2020)
  • Known sensitivity to ATX
  • Subjects with major traumatic brain injury (TBI) determined by Ohio State University Traumatic Brain Injury Identification Method (OSU-TBI ID)
  • However, mild TBI, assessed with OSU-TBI ID and review of record will be allowed to participate in this trial
  • Prominent suicidal or homicidal ideation or any suicidal behavior in the past 3 months on the Columbia Suicide Severity Rating Scale (C-SSRS)

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Ralph H. Johnson VA Medical Center, Charleston, SCCharleston, Egyesült ÁllamokContact: Sarah A Jackson, BA MARésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Attention deficits (AD) frequently co-occur with posttraumatic stress disorder (PTSD). The presence of AD is associated with greater PTSD clinical severity and poorer clinical outcomes. Knowledge regarding the mechanism underlying this association is limited, though the emerging evidence has indicated that executive function deficit (EFD) is strongly correlated with AD and PTSD symptoms. While treatments developed for PTSD have existed for years, a substantial portion of individuals do not fully respond to conventional treatment. Accumulating evidence suggest that attention deficit (AD) and EFD may be a driving force for PTSD treatment resistance. However, treatment of executive impairment in PTSD is very limited. As a result, untreated co-occurring AD and EFD in PTSD poses severe negative impacts on patients' functional recovery, treatment outcomes, and quality of life (QoL). Given that up to 50% of patients do not respond well to the first-line pharmacological PTSD treatments, it is imperative to seek novel treatment strategies to improve EF that may improve both standard treatment response and QoL, social function. The proposed study directly addresses this knowledge gap by testing the efficacy of atomoxetine (ATX) in improving EF and attention among Veterans with PTSD, which will further improve Veterans' QoL and social function. ATX represents a promising novel candidate pharmacotherapy for individuals with PTSD. ATX is a non-stimulant selective norepinephrine reuptake inhibitor (SNRI), approved by the FDA for the treatment of ADHD. Studies suggest that ATX, unlike stimulants, lacks addictive properties and shows efficacy in the treatment of comorbid depression and anxiety, which is ideal in the treatment of PTSD. Data from the investigators' preliminary study provides encouraging support for the therapeutic potential of ATX in improving EF in Veterans with comorbid PTSD/ADHD. The investigators' recent research uncovered a higher rate of ADHD among Veterans with PTSD, and the comorbid AD symptoms were correlated with PTSD severity and poorer treatment outcomes. Treatment with ATX showed significant symptoms reduction in ADHD and improvement in inhibitory function in Veterans with ADHD/PTSD. In the proposed study, the investigators will focus on ATX in improvement of EF and attention, and further psycho-social life function and QoL. The investigators will (1) employ a randomized, double-blind design that will consist of 12 weeks of treatment with ATX or placebo medication; (2) use standardized, repeated dependent measures to rigorously assess AD and EFD symptomatology; (3) measure impairment in associated mental and behavioral health problems (e.g., attention deficit, depression, anxiety, suicidality, QoL, family/social functioning); and (4) use response inhibition task GoNogo, working memory and attention tests Digit Span and Trail Making to investigate the underlying pathophysiology of PTSD and prognostic indicators of treatment outcome. To achieve these goals, the investigators have assembled a multidisciplinary team with expertise in PTSD, ADHD clinical trials, and human laboratory paradigms who have successfully collaborated in the past and are uniquely qualified to implement this type of investigation. The proposed project is directly responsive to the mission of the VA-RRD "to maximize Veterans' functional independence, quality of life and participation in their lives and community." Successful completion of this study will provide a platform for a large multi-center trial to further confirm the important role of EF in PTSD treatment outcomes. The findings from this study will provide critically needed evidence to help inform clinical practice guidelines on the treatment of PTSD. The outcome of the proposed research will be significant, because it provides a knowledge base to allow for development of new PTSD intervention strategies. More importantly, this clinical trial may immediately benefit Veterans by enhancing their cognitive function, reducing AD related disability, and further improving quality of life for Veterans who suffer from PTSD.

A vizsgálat 2 csoportja

  • active atomoxetineA vizsgált kezelés

    Active ATX (40mg capsules) will be prepared. Initial dose is 40mg, titrated to 80mg if tolerable in one week.

    Kezelés: Atomoxetine

  • PlaceboPlacebo, összehasonlításként

    placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder
Kérdések a feltételekről
Forrás: NCT06573970: ki vehet részt
A regiszteradat frissítve
2026. július 7.